Hepatocellular carcinoma screening and surveillance practice guidelines and real-life practice

Journal of Clinical Gastroenterology

Volumn 50, Issue 2, 2016, Pages 120-133

  Zhao, Changqing ^a,b   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Adherence; Compliance; Liver cancer; Routine practice

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL PRACTICE; CONSENSUS; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; LIVER CELL CARCINOMA; MEDICAL SOCIETY; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; REVIEW; STRATEGIC PLANNING; CARCINOMA, HEPATOCELLULAR; EARLY CANCER DIAGNOSIS; LIVER NEOPLASMS; PATIENT COMPLIANCE; PATIENT SELECTION; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TRENDS;

CARCINOMA, HEPATOCELLULAR; CONSENSUS; EARLY DETECTION OF CANCER; GUIDELINE ADHERENCE; HUMANS; LIVER NEOPLASMS; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84955330908     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000446     Document Type: Review

References (145)

1. WHO. Screening for various cancers. Available at: http://www.who.int/cancer/detection/variouscancer/en/. Accessed February 10, 2015.
2. Feig SA. Decreased breast cancer mortality through mammo-graphic screening: results of clinical trials. Radiology. 1988;167:659-665.
3. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-437.
4. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000;36:2209-2214.
5. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9:617-623.e611.
6. Eskens FA, van Erpecum KJ, de Jong KP, et al. Hepatocel-lular carcinoma: Dutch guideline for surveillance, diagnosis and therapy. Neth J Med. 2014;72:299-304.
7. Kapitanov T, Neumann UP, Schmeding M. Hepatocellular carcinoma in liver cirrhosis: surgical resection versus trans-arterial chemoembolization-A meta-analysis. Gastroenterol Res Pract. 2015;2015:696120.
8. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136: E359-E386.
9. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
10. Chiba T, Matsuzaki Y, Abei M, et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol. 1996;91:1195-1203.
11. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
12. Segi M, Fujisaku S. Cancer Mortality for Selected Sites in 24 Countries (1950-1957). Sendai: Department of Public Health, Tohoku University School of Medicine; 1960.
13. Doll R, Payne P, Waterhouse JAH. Cancer Incidence in Five Continents, Vol. 1. Geneva: Union Internationale Contre le Cancer; 1966.
14. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308.
15. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://www.globocan.iarc.fr/Default.aspx. Accessed February 10, 2015.
16. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(suppl 4):5-13.
17. Tanioka H, Omagari K, Kato Y, et al. Present status of hepatitis virus-associated hepatocellular carcinoma in Nagasaki Prefecture, Japan: a cross-sectional study of 1019 patients. J Infect Chemother. 2002;8:64-69.
18. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044.
19. Ferenci P, Fried M, Labrecque D, et al. World Gastro-enterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311-317.
20. Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2009;286:5-8.
21. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastro-enterology. 2004;127:S35-S50.
22. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942-1956.
23. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12, 008 men in Taiwan. Am J Epidemiol. 2003;157: 674-682.
24. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology. 1994;106:1000-1005.
25. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842-846.
26. Sakuma K, Saitoh N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 1988;8: 1642-1646.
27. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145:1039-1047.
28. Evans AA, Chen G, Ross EA, et al. Eight-year follow-up of the 90, 000-person Haimen City cohort: I. Hepato-cellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11: 369-376.
29. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294-298.
30. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology. 1999;30:257-264.
31. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol. 1999;94: 2246-2250.
32. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263-270.
33. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334: 1422-1427.
34. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306-313.
35. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986;90: 263-267.
36. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975.
37. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21: 650-655.
38. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930-938.
39. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-2895.
40. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-147.
41. Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998;83: 901-909.
42. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999;85:2132-2137.
43. Liaw YF, Lin DY, Chen TJ, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9:235-241.
44. Oon CJ. Long-term survival following treatment of hepato-cellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol. 1992;31(suppl):S137-S142.
45. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer. 1994;74:2234-2238.
46. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998;82: 827-835.
47. Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996;23:695-699.
48. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94-99.
49. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-181.
50. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124-1130.
51. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003;37: 520-527.
52. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-1695.
53. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758.
54. Gramenzi A, Andreone P, Fiorino S, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut. 2001;48:843-848.
55. Mazziotti G, Sorvillo F, Morisco F, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002;95:2539-2545.
56. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435-1440.
57. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136.
58. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatol-ogy. 1998;28:562-567.
59. Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870-1875.
60. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28:921-925.
61. Kuper H, Ye W, Broome U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology. 2001;34:714-718.
62. Adami HO, Hsing AW, McLaughlin JK, et al. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer. 1992;51:898-902.
63. Henrion J, Libon E, De Maeght S, et al. [Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin]. Gastroenterol Clin Biol. 2003;27:534-539.
64. Serra MA, Escudero A, Rodriguez F, et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol. 2003;36:170-174.
65. Miyakawa H, Izumi N, Marumo F, et al. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res. 1996;20:91a-94a.
66. Uetake S, Yamauchi M, Itoh S, et al. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen-and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res. 2003;27:47s-51s.
67. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 1999;30:653-659.
68. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196-197.
69. Tarao K, Rino Y, Ohkawa S, et al. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer. 2002;94: 1787-1795.
70. Mair RD, Valenzuela A, Ha NB, et al. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol. 2012;10:1412-1417.
71. Simonetti RG, Camma C, Fiorello F, et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36:962-972.
72. El-Serag HB. Epidemiology of viral hepatitis and hepato-cellular carcinoma. Gastroenterology. 2012;142:1264-1273. e1261.
73. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
74. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119-126.
75. Abe R, Okano J, Imamoto R, et al. Evaluation of the surveillance program for hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi. 2012;109:741-750.
76. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.
77. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
78. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010; 46:744-751.
79. Ye SL, Takayama T, Geschwind J, et al. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15(suppl 4):34-41.
80. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
81. Bruix J, Sherman M. Management of hepatocellular carci-noma. Hepatology. 2005;42:1208-1236.
82. EASL-EORTC. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908-943.
83. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommen-dations on hepatocellular carcinoma. Hepatol Int. 2010; 4:439-474.
84. KASL. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162.
85. Ministry of Health of the People s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma. J Clin Hepatol. 2011;27:1141-1159.
86. Verslype C, Rosmorduc O, Rougier P, et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii41-vii48.
87. Benson AB III, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391.
88. Bruix J, Sherman M. Management of hepatocellular carci-noma: an update. Hepatology. 2011;53:1020-1022.
89. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-364.
90. Borzio M, Fornari F, De Sio I, et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol. 2013;9:283-294.
91. Aberra FB, Essenmacher M, Fisher N, et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160.
92. Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432.
93. Huang YC, Huang CF, Chang KC, et al. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B-and C-endemic area. J Gastroenterol Hepatol. 2011;26:129-134.
94. Lee EH, Han MA, Lee HY, et al. Liver cancer screening in Korea: a report on the 2008 National Cancer Screening Programme. Asian Pac J Cancer Prev. 2010;11:1305-1310.
95. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204-209.
96. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-259.
97. Sherman M, Peltekian KM, Lee C. Screening for hepatocel-lular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22: 432-438.
98. Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 1994;20:65-71.
99. Sarkar M, Shvachko VA, Ready JB, et al. Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci. 2014;59:2100-2108.
100. Ly CL, Wong LL. Ethnicity as a predictive factor for hepatocellular carcinoma screening among patients in Hawaii. Ethn Dis. 2014;24:376-381.
101. Palmer LB, Kappelman MD, Sandler RS, et al. Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population. J Clin Gastroenterol. 2013;47:713-718.
102. Sarkar M, Stewart S, Yu A, et al. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat. 2012;19: 594-600.
103. El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992-997.
104. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154:85-93.
105. Tong MJ, Sun HE, Hsien C, et al. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826-835.
106. Tong MJ, Chavalitdhamrong D, Lu DS, et al. Survival in Asian Americans after treatments for hepatocellular carci-noma: a seven-year experience at UCLA. J Clin Gastroenterol. 2010;44:e63-e70.
107. Jou JH, Chen PH, Jazwinski A, et al. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci. 2010;55:3591-3596.
108. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52: 132-141.
109. Wong CR, Garcia RT, Trinh HN, et al. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54:2712-2721.
110. Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology. 2008;48:1149-1156.
111. Leykum LK, El-Serag HB, Cornell J, et al. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastro-enterol Hepatol. 2007;5:508-512.
112. Davila JA, Weston A, Smalley W, et al. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41:777-782.
113. Widjaja D, Yarlagadda S, Singu BS, et al. Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. J Natl Med Assoc. 2007;99:384-388.
114. Wong LL, Limm WM, Severino R, et al. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000;6:320-325.
115. Wong N, Haydon A, Kemp W, et al. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J. 2013;43:197-203.
116. Chan AC, Poon RT, Ng KK, et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg. 2008;247:666-673.
117. Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J. 2007;37:516-522.
118. Toyoda H, Kumada T, Kiriyama S, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol. 2006;4:1170-1176.
119. Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543-551.
120. Cheung TK, Lai CL, Wong BC, et al. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573-583.
121. Ando E, Kuromatsu R, Tanaka M, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease. J Clin Gastroenterol. 2006;40:942-948.
122. Taura N, Hamasaki K, Nakao K, et al. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospi-tal-based study. Oncol Rep. 2005;14:999-1003.
123. Miquel M, Sopena J, Vergara M, et al. Factors related to survival in hepatocellular carcinoma in the geographic area of Sabadell (Catalonia, Spain). Rev Esp Enferm Dig. 2012;104: 242-247.
124. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397-405.
125. Zapata E, Zubiaurre L, Castiella A, et al. Are hepatocellular carcinoma surveillance programs effective at improving the therapeutic options. Rev Esp Enferm Dig. 2010;102: 484-488.
126. Pascual S, Irurzun J, Zapater P, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int. 2008;28:682-689.
127. Trevisani F, Santi V, Gramenzi A, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007;102:2448-2457. quiz 2458.
128. Caumes JL, Nousbaum JB, Bessaguet C, et al. Epidemiology of hepatocellular carcinoma in Finistere. Prospective study from June 2002 to May 2003. Gastroenterol Clin Biol. 2007;31:259-264.
129. Van Vlierberghe H, Colle I, Henrion J, et al. The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC? Acta Gastroenterol Belg. 2005;68: 403-411.
130. Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepato-cellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97: 734-744.
131. Singal AG, Yopp A, SS C, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27:861-867.
132. Farinati F, Sergio A, Giacomin A, et al. Is female sex a significant favorable prognostic factor in hepato-cellular carcinoma? Eur J Gastroenterol Hepatol. 2009;21: 1212-1218.
133. Nguyen TT, Gildengorin G, Truong A, et al. Factors influencing physicians' screening behavior for liver cancer among high-risk patients. J Gen Intern Med. 2007;22: 523-526.
134. Robotin MC, Kansil MQ, George J, et al. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res. 2010;10:215.
135. McGowan CE, Edwards TP, Luong MU, et al. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol. 2015;13:799-804.
136. Dalton-Fitzgerald E, Tiro J, Kandunoori P, et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:791-798.e791.
137. Saab S, Nguyen S, Ibrahim A, et al. Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006;40:156-161.
138. Patwardhan V, Paul S, Corey KE, et al. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56:3316-3322.
139. Fleming LE, Pitman T, LeBlanc WG, et al. Occupations and Health Disparities: The National Health Interview Survey 1997-2004. 2007 Available at: http://www.umiamiorg.com/publications/monograph/health-disparities.html. Accessed February 10, 2015.
140. Clarke TC, Soler-Vila H, Fleming LE, et al. Trends in adherence to recommended cancer screening: the US Pop-ulation and Working Cancer Survivors. Front Oncol. 2012;2:190. doi:10.3389/fonc.2012.00190.
141. Jerant A, Fiscella K, Tancredi DJ, et al. Health insurance is associated with preventive care but not personal health behaviors. J Am Board Fam Med. 2013;26:759-767.
142. Sharma P, Saini SD, Kuhn LB, et al. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577.
143. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477.
144. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012;5:1124-1130.
145. Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13:172-179.